Research published today in Microbiology Spectrum, a journal of the American Society for
Microbiology states that genetic testing of saliva samples identifies the SARS-CoV-2 virus more quickly than testing of nasal swabs.
“That is important because people can spread COVID-19 before they know that they have it,” said co-author Donald K. Milton, M.D., DrPH, a professor of occupational and environmental health at the Institute for Applied Environmental Health, University of Maryland School of Public Health, College Park. “Earlier detection can reduce the disease’s spread.”
The research was motivated by the problem that early in the pandemic, an urgent need to increase testing was accompanied by a shortage of supplies, notably nasal swabs, which were then the standard method for collecting samples for testing.
To identify people with COVID-19 the investigators began conducting weekly tests of saliva samples from healthy community volunteers in May 2020 and continued over the next two years. Of the asymptomatic volunteers who tested positive, Milton and his colleagues found that those patients would typically show symptoms a day or two later. “That made us wonder whether saliva was better for catching pre-symptomatic patients than the traditional nasal swabs,” he said.
To answer that question, the researchers used data from a companion study of close contacts of people with confirmed cases of COVID-19. In the study, “We collected saliva and mid-turbinate [nasal] swab samples from contacts every two or three days during their quarantine period,” said Milton. “All samples were tested using real-time reverse transcription polymerase chain reaction [RT-PCR] to detect SARS-CoV-2 and measure how much viral RNA was in the samples. We then analysed how these results changed in the days before and after symptom onset.”
“Early in the course of infection, saliva was significantly more sensitive than mid-turbinate nasal swabs,” notably so before onset of symptoms, according to the study, which noted that previous studies had shown that pre-symptomatic transmission plays a greater role than symptomatic transmission of SARS-CoV-2.
The findings have implications for improving public acceptance of COVID-19 testing, reducing the cost of mass COVID-19 screening and improving the safety of healthcare workers who conduct testing. In the latter case, saliva self-testing avoids the close contact between patient and healthcare worker that nasal swabbing entails and avoids causing patients to cough and sneeze, thereby spreading virus particles as a result of swabbing the sensitive nasal passages, as well as discomfort to patients.
Graham Gordon, CEO of Gardian and developer of the Gardian T3 saliva-based rapid antigen test said: “This research supports the use of saliva in large-scale screening in schools and workplaces, as a means of improving screening rates, as well as early detection. And now that there is a rapid, very highly sensitive saliva test available in Australia, they look set to be a major advance from the current nasal swab-based rapid tests.”
About the American Society for Microbiology
The American Society for Microbiology is one of the largest professional societies dedicated to the life sciences and is composed of 30,000 scientists and health practitioners. ASM's mission is to promote and advance the microbial sciences.
About Gardian T3
Gardian T3 Covid-19 SARS-CoV-2 Antigen Saliva Self Test is a qualitative lateral flow immunoassay intended to detect SARS-CoV-2 nucelocapsid antigens present in human saliva samples in vitro.
The Gardian T3 Saliva Covid-19 Self Test Kit includes the Gardian Self Check App to assist with completing the test, storing the result and proving your COVID-19 test status.
Click here to learn more about Gardian T3.